H1L1A1B3-circRNA-IL-12 LNP

H1L1A1B3-circRNA-IL-12 LNP is an experimental immunotherapy consisting of circular RNA (circRNA) encoding Interleukin-12 (IL-12) encapsulated in a specialized ionizable lipid nanoparticle (LNP) designated H1L1A1B3. Developed by researchers at Baylor College of Medicine, UTSW, and the University of Toronto, this platform utilizes circRNA to achieve more sustained protein expression compared to traditional linear mRNA. The H1L1A1B3 LNP was identified through high-throughput screening using the Ugi reaction and serves a dual function: it efficiently delivers the circRNA cargo and acts as an immune adjuvant by activating the NF-κB and IRF innate immune pathways. In preclinical lung cancer models, local administration (intratumoral or intratracheal) resulted in sustained IL-12 and IFN-γ expression, remodeling the tumor microenvironment to enhance T-cell infiltration and suppress tumor growth without significant systemic toxicity.

Other names

IL-12 circRNA LNPsIL12 circRNA LNPsIL 12 circRNA LNPsH1L1A1B3-circRNA-IL-12H-1L1A1B3-circRNA-IL-12H 1L1A1B3-circRNA-IL-12